Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients

  • Naoki Horikawa1,
  • Tsukasa Baba1Email author,
  • Noriomi Matsumura1,
  • Ryusuke Murakami1,
  • Kaoru Abiko1,
  • Junzo Hamanishi1,
  • Ken Yamaguchi1,
  • Masafumi Koshiyama1,
  • Yumiko Yoshioka1 and
  • Ikuo Konishi1
BMC Cancer201515:739

https://doi.org/10.1186/s12885-015-1703-1

Received: 29 January 2015

Accepted: 7 October 2015

Published: 19 October 2015

Abstract

Background

Neoadjuvant chemotherapy (NAC) using platinum and irinotecan (CPT-11) followed by radical excision has been shown to be a valid treatment for locally advanced squamous cervical cancer (SCC) patients. However, in NAC-resistant or NAC-toxic cases, surgical treatment or radiotherapy might be delayed and the prognosis may be adversely affected. Therefore, it is important to establish a method to predict the efficacy of NAC.

Methods

Gene expression microarrays of SCC tissue samples (n = 12) and UGT1A1 genotyping of blood samples (n = 23) were investigated in terms of their association with NAC sensitivity. Gene expression and drug sensitivity of SCC cell lines were analyzed for validation.

Results

Microarray analysis revealed that the glutathione metabolic pathway (GMP) was significantly up-regulated in NAC-resistant patients (p < 0.01), and there was a positive correlation between 50 % growth inhibitory concentrations of CPT-11 and predictive scores of GMP activation in SCC cells (r = 0.32, p < 0.05). The intracellular glutathione (GSH) concentration showed a highly positive correlation with GMP scores among 4 SCC cell lines (r = 0.72). UGT1A1 genotyping revealed that patients with UGT1A1 polymorphisms exhibited significantly higher response rates to NAC than those with the wild-type (79.5 vs. 49.5 %, respectively, p < 0.05).

Conclusions

These results indicate that GMP scores of cancerous tissue combined with UGT1A1 genotyping of blood samples may serve as highly potent markers for predicting the efficacy of NAC for individual SCC patients.

Keywords

Neoadjuvant chemotherapyCervical cancerBioinformaticsGlutathione pathwayUGT1A1 polymorphism

Background

Despite the prevalence of screening and advancement of therapy, the mortality rate among women of reproductive age due to cervical cancer has increased over the last two decades in Japan [1]. As locally advanced cervical cancer (LACC) of FIGO stage Ib2 or IIb is frequently accompanied by lymph node metastasis, patients bearing LACC, treated only with excision or radiation, exhibit a high incidence of recurrence, resulting in a poor survival outcome [2]. Thus, radical hysterectomy (RH) coupled with platinum-based chemotherapy or radiation and concurrent chemo-radiation therapy are now employed as intensive treatments for LACC [3, 4]. Neoadjuvant chemotherapy (NAC) prior to RH is usually conducted to reduce the tumor volume and improve the safety and integrity of surgery, but the prognosis of NAC-refractory patients worsens with the delay of the main treatment [4]. Therefore, to optimize the efficacy of NAC-RH, a method is needed to exclude chemo-refractory cases before starting initial therapy.

Recently, genomic characterization by analyzing gene expression microarrays or genotyping onco-related/suppressive genes has been developed to evaluate characteristic profiles of chemo-refractory tumors and host patients [5, 6]. Single-sample Gene Set Enrichment Analysis (ssGSEA) is a bioinformatics method to characterize the biological features of individual samples as signature scores based on gene expression microarrays [7]. It was reported that the TP53 pathway ssGSEA score can be used to predict the response of lung cancer to radiation [8], but there has been no report suggesting that ssGSEA is useful to predict the chemo-susceptibility of LACC. On the other hand, it is well-known that irinotecan (CPT-11) causes severe side effects more frequently in patients with UGT1A1 polymorphisms than the wild-type [9], and, thus, UGT1A1 genotyping is a prerequisite before initiating chemotherapy using CPT-11 in a clinical setting. However, it remains unclear whether CPT-11 treatment is more effective in LACC patients with UGT1A1 polymorphisms. In this study, we assessed whether the chemo-susceptibility of LACC could be evaluated based on tumor expression microarray analysis and host UGT1A1 genotyping, in order to optimize the efficacy of NAC-RH.

Methods

Sampling and intervention

A total of 209 cervical cancer patients underwent primary therapy in the 5 years between 2007 and 2012. NAC-RH was administered to patients with stage Ib2 tumors larger than 4 cm or stage IIb tumors who did not desire radiotherapy, with 38 of the 209 patients meeting this criterion. The clinicopathological characteristics of these 38 LACC patients treated with NAC-RH from 2007 to 2012 at Kyoto University Hospital are summarized in Table 1. Peripheral blood samples from 23 patients were collected before the operation and their genomic DNA was extracted using a QIAamp blood kit (QIAGEN, Tokyo, Japan). Cancerous tissues were obtained from patients during the surgery, and their RNA was extracted using the RNeasy Mini Kit (QIAGEN). The RNA integrity number (RIN) was assessed with a bio-analyzer, and 12 samples with an RIN above 7.0 underwent further gene expression analysis (Additional file 4: Table S1). All materials were obtained following the receipt of written consent and used based on protocols approved by the Kyoto University Institutional Review Board. All patients received 1 to 3 courses of the combined therapy of CPT-11 and Nedaplatin (NDP) every 3 weeks before undergoing the surgery, as previously described: CPT-11, 60 mg/m2 on days 1 and 8; NDP, 60 mg/m2 on day 1 [10]. After the surgery, a total of 31 patients received 3 to 4 courses of CPT-11/NDP, 6 patients underwent other treatments because of CPT/NDP resistance, and 1 patient declined postsurgical treatment. Magnetic resonance imaging (MRI) was conducted before initiating chemotherapy and after the completion of each course until surgery. The tumor shrinkage rate was calculated based on the largest diameter of the target lesion on MRI according to the response evaluation criteria in solid tumors (RECIST) [11]. Patients underwent modified Okabayashi’s RH [12] at the point of achieving favorable or improbable responses after 1 (n = 4), 2 (n = 33), or 3 (n = 1) courses of chemotherapy. Adverse events during NAC were evaluated according to the Common Terminology Criteria for Adverse Events [13].
Table 1

Characteristics of LACC patients treated with NAC followed by RH

Characteristics

Number

%

Total patients

38

 

Median age (range)

49 (25–69)

 

Performance status 0

38

100

FIGO stage

 1B2

12

31.6

 2B

26

68.4

Pathology

 Squamous

36

94.7

 Adenosquamous

2

5.3

Primary tumor size

 >4 cm

30

78.9

4 cm

8

21.1

Tumor response after NAC

 CR

5

13.2

 PR

24

63.1

 SD

8

21.1

 PD

1

2.6

Shirinkage rate

 >50 %

25

65.8

50 %

13

34.2

Lymph node metastasis

 negative

23

60.5

 positive pelvic

15

39.5

 positive aortic

4

10.5

Recurrence

10

26.3

CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease

Cell lines and culture

Human cervical cancer cell lines: Ca-ski, SKGIIIa, Hela, and ME-180, were obtained from Riken BioResource Center (Tsukuba, Japan) and maintained in RPMI1640 (Nacalai Tesque, Kyoto, Japan) and DMEM (Gibco, Grand Island, NY, USA) supplemented with 10 % heat-inactivated fetal bovine serum (v/v; Biowest, France) and penicillin–streptomycin (100 IU/mL penicillin, 100 μg/mL streptomycin; Nacalai Tesque). All of them are representative cervical cancer cell lines, and their gene expression microarray data could be obtained with IC50 values for CPT-11 from the COSMIC dataset.

Microarray analysis

Transcriptional gene expression microarrays were generated from 12 cervical cancer samples using U133 Plus 2.0 gene chips (Affymetrix, Santa Clara, CA, USA), and Robust Multi-Array Average (RMA) normalization was performed using R (version 2.15.1). Microarray data can be obtained at the Gene Expression Omnibus website (GSE70035, http://www.ncbi.nlm.nih.gov/geo/). Probes showing expression values >5.0 in at least one sample and standard deviation >0.2 across all samples were filtered to perform gene expression analysis with differentially expressed genes, and the SAMROC method [14] was used for statistical analysis, as previously described [15]. Gene Set Enrichment Analysis (GSEA) was performed using the Molecular Signatures Database (http://www.broad. mit.edu/gsea/msigdb/index.jsp). A variant of GSEA, single-sample GSEA (ssGSEA), was performed using R to predict gene signature activity in squamous cell carcinoma (SCC) cells based on the Catalogue Of Somatic Mutation In Cancer (COSMIC, http://cancer.sanger.ac.uk/cosmic) and HCT116 cells, colon cancer cell lines, web-published at Array Express: E-MEXP-1171, as well as our own samples.

UGT1A1 genotyping and glutathione assay

The Invader UGT1A1 Molecular Assay Kit (Third Wave Technologies, Madison, WT, USA) was used to detect UGT1A1*6 and UGT1A1*28 polymorphisms of genomic DNA derived from blood samples. Regarding cell line samples, the polymerase chain reaction (PCR) was carried out to amplify the characteristic regions using designed primers (Greiner Bio-One, Tokyo, Japan), and UGT1A1 polymorphisms were determined by direct sequencing, as previously described [16].

Primers: UGT1A1*28 forward: 5’-TATA GTCACGTGACACAGTC’-3 and reverse: 5’-CCACTGGGATCAACAGTATCT’-3, UGT1A1*6 forward: 5’-AAGTAGGAGAGGGCGAACC’-3 and reverse: 3’-GTGGGCAGAACAGGTACT’-3.

Total GSH concentrations in cancer cells were assayed using the total GSH Quantification Kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s protocol.

Statistical analyses

Group comparisons were made using the Mann–Whitney U test or Fisher’s exact test. Prognostic analyses were performed using the Log-rank and Cox proportional hazard tests. All statistical analyses were conducted using R software. Two-side probability values below 0.05 were considered significant.

Results

Characteristics of patients treated with NAC-RH

Clinical characteristics of the 38 LACC patients treated with NAC-RH are listed in Table 1 (median age: 49 years old, stage Ib2: n = 12, IIb: n = 26). Among these patients, 29 (76.3 %) exhibited a complete or partial response to NAC, and the tumor shrinkage rate exceeded 50 % in 25 patients. However, post-NAC pathological findings revealed node metastasis in 19 patients, resulting in recurrence in 10 patients. In DFS analysis (Table 2), the age, tumor size, and serum SCC values before treatment were not significant prognostic factors. Known major risk factors of recurrence, stage and node metastasis, were not determinants in this study, but lymphovascular invasion (LVSI) and a tumor shrinkage rate below 50 % exhibited significant differences regarding DFS (p < 0.05, Table 2). The Cox proportional hazard test revealed that a tumor shrinkage rate below 50 % was an independent risk factor (RR: 12.14, p < 0.05, Table 2 and Additional file 1: Figure S1), and patients with a rate < 50 % were defined as non-responders for further analysis.
Table 2

Univariate and multivariate analyses of factors predicting disease-free survival (n = 38)

 

Univariate

Multivariate

 

RR

95 % CI

P-value

RR

95 % CI

P-value

Age

1.149

0.3154 – 4.190

0.8328

1.162

0.1601 – 4.622

0.8607

FIGO stage

1.877

0.4963 – 7.102

0.3535

2.524

0.2284 – 27.89

0.4501

Lymph node metastasis

1.937

0.5174 – 7.248

0.3263

1.197

0.4152 – 8.85

0.4044

Parametrium invasion

3.155

0.9579 – 11.76

0.0681

1.716

0.0402 – 8.416

0.691

Margin positive

3.884

0.3645 – 685.0

0.1581

1.604

0.03867 – 10.06

0.7392

Primary tumor > 4 cm

0.3786

0.05758 – 1.266

0.1609

0.3811

0.2314 – 29.76

0.4362

Serum SCC antigen > 5.0 ng/mL

0.6878

0.1982 – 2.365

0.5545

0.2663

0.04308 – 1.646

0.1545

LVSI

8.698

1.508 – 18.00

0.011*

9.764

0.7944 – 120.0

0.07506

Shrinkage rate 50 %

6.098

2.328 – 37.18

0.0021*

12.14

1.023 – 144.1

0.04794*

RR Relative risk, CI Confidence interval, Univariate analysis, Log rank test; Multivariate analysis, Cox proportional hazard model; *significant p-value

Analysis of expression profiles of clinical samples

Gene expression microarrays of 12 post-NAC tumors were analyzed to determine the representative signature of chemo-susceptibility in LACC, in order to compare NAC responders (shrinkage rate50 %, n = 6) with non-responders (rate <50 %, n = 6). SAMROC analysis detected 35 genes that were significantly up-regulated in non-responders (p < 0.001, Fig. 1), including drug-metabolism-related molecules such as ALDH3A1 (aldehyde dehydrogenase 3 family, member A1) and GPX2 (glutathione peroxidase 2). GSEA analysis revealed that metabolism-related and DNA repair system-related pathways were significantly up-regulated in non-responders (Table 3). The constitutive genes of the glutathione metabolic pathway (GMP) and mismatch repair pathway are shown in Additional file 4: Table S2. In ssGSEA analysis, the GMP score was significantly higher in non-responders (p < 0.01), while there was no significant difference in the mismatch repair pathway score (p = 0.1846, Fig. 2a). The prominent expression of GMP genes, GPX2, GSS, and GCLM, was confirmed in NAC-responders by qPCR (Fig. 2b).
Fig. 1

Expression pattern of discriminating genes of post-NAC tumors between responders (shrinkage rate 50 %) and non-responders (shrinkage rate < 50 %) among 12 LACC patients. The listed genes were extracted by comparative analysis using the SAMROC method with a p-value <0.001. Vertical columns represent individual samples, and the table at the bottom provides data on the shrinkage rate, LVSI, and UGT1A1 polymorphism. Concerning UGT1A1 polymorphism, 1, 6, and NA indicate “UGT1A1 *1/*1 (UGT1A1-wild),” “heterozygotic polymorphism of UGT1A1 *1/*6,” and “not available” respectively

Table 3

Genomic comparison between NAC-responders and non-responders. Enriched KEGG pathways in non-responders with shrinkage rates 50 %

KEGG pathway

Number of genes

NES

p-value

q-value

Metabolism-related

 METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450

34

2.021684

<0.01

<0.001

 DRUG_METABOLISM_CYTOCHROME_P450

36

1.987058

<0.01

0.002063

 PROPANOATE_METABOLISM

29

1.925244

<0.01

0.001375

 VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION

41

1.920898

<0.01

0.001179

 BUTANOATE_METABOLISM

26

1.873636

<0.01

0.003011

 GLUTATHIONE_METABOLISM

42

1.652794

<0.01

0.031592

DNA repair system-related

 MISMATCH_REPAIR

21

1.935372

<0.01

0.00165

 HOMOLOGOUS_RECOMBINATION

23

1.754282

<0.01

0.009237

 BASE_EXCISION_REPAIR

33

1.62332

<0.01

0.041855

 NUCLEOTIDE_EXCISION_REPAIR

42

1.588174

<0.01

0.042931

Others

 DNA_REPLICATION

33

2.245259

<0.01

<0.001

 CELL_CYCLE

107

2.148499

<0.01

<0.001

 ALDOSTERONE_REGULATED_SODIUM_REABSORPTION

25

1.668492

0.019608

0.027948

 GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR

23

1.597785

0.017544

0.042713

KEGG Kyoto Encyclopedia of Genes and Genomes Database, NES Normalized Enrichment Score

Fig. 2

a Comparison of ssGSEA scores of glutathione metabolism and mismatch repair pathways between NAC-responders (n = 6) and non-responders (n = 6). The Mann–Whitney U test was used for statistical analysis of the two groups. b Relative expressions of GMP genes, GPX2, GSS, and GCLM, were compared between NAC-responders and non-responders based on quantitative PCR

GMP score shows a positive correlation with resistance to CPT-11

Using published COSMIC gene expression profiles of 57 SCC cell lines with half maximal inhibitory concentrations (IC50 values) for various anticancer drugs, ssGSEA analysis was performed. GMP scores exhibited a positive correlation with IC50 values for CPT-11 (r = 0.32, p < 0.05, Additional file 2: Figure S2A), but not with cisplatin. ssGSEA also showed that GMP scores of HCT-116 cells were significantly higher in CPT-11-resistant derivatives (p < 0.05, Additional file 2: Figure S2B). These results indicated that the GMP score could be a potent marker of resistance to CPT-11.

To confirm the validity of the GMP score, the total intracellular glutathione concentration (GSH) resulting from glutathione metabolism was assessed in the 4 cultured cervical cancer cell lines. There was a positive correlation between GSH and GMP (r = 0.72), and, under treatment with CPT-11, apoptosis was induced in Ca-ski and ME-180 cells with low GMP and/or GSH scores in a dose-dependent manner (Fig. 3a). Furthermore, GPX2 and GCLM were more highly expressed in Hela and SKGIIIa cells, along with a high GSH concentration (Additional file 2: Figure S2C).
Fig. 3

Genomic analysis of cervical cancer cell lines. a Left: Correlation analysis of GMP scores with intracellular GSH concentrations within 4 cervical cancer cell lines (n = 5). GMP scores were correlated with the total GSH concentration (r = 0.72). Right: Apoptosis was induced in each cell line in the presence of several concentrations of CPT-11 (0, 10, or 100 μM). *: p < 0.05. n.s.: not significant. b Targeted sequencing of the UGT1A1 gene in SKGIIIa. UGT1A1*28 polymorphism is designated as two base pair insertions of TA in the TATA box within the promoter region of the UGT1A1 gene. The A(TA)6TAA sequence in the wild-type allele become A(TA)7TAA in UGT1A1*28 polymorphism. Heterozygous UGT1A1*28 polymorphism exhibited waveform distortion downstream of the promoter region of the gene

SKGIIIa exhibited a high GMP score, although it was designated as CPT-11-sensitive (Additional file 2: Figure S2A). Interestingly, UGT1A1 polymorphism analysis revealed the presence of UGT1A1*28 heterozygotic polymorphism in SKGIIIa cells (Fig. 3b), indicating the contribution of host UGT1A1 polymorphisms to the susceptibility of tumors to CPT-11.

Clinical impact of UGT1A1 polymorphism

UGT1A1 genotyping of patients’ blood samples led to the detection of heterozygotic polymorphisms (*1/*6, *1/*28) in 11 patients (48 %, UGT1A1-poly), while almost half of the patients were UGT1A1 *1/*1 (UGT1A1-wild), and there were no patients with homozygotic (*6/*6, *28/*28) or compound heterozygotic (*6/*28) polymorphisms in this study. The tumor size was significantly reduced by NAC in UGT1A1-poly patients (77.5 %) compared with UGT1A1-wild patients (49.5 %, p < 0.05), although there were no differences in severe adverse events between them (Table 4).
Table 4

Association between UGT1A1 genotypes and either prognostic factors or Grade 3 to 4 toxicities (n = 23)

UGT1A1 genotypes

*1/*6 or*1/*28

*1/*1

p

n = 11

n = 12

Prognostic factors

 LVSI

5 (45 %)

6 (50 %)

0.827

 Shrinkage rate (median +/− SD %)

77.5 +/− 26.8

49.5 +/− 24.1

0.028*

G3/4 Toxicities

 Neutropenia

6 (54.5 %)

8 (66.7 %)

0.552

 Leukopenia

4 (36.4 %)

3 (25.0 %)

0.554

 Anemia

2 (18.2 %)

1 (8.3 %)

0.484

 Thrombocytopenia

1 (9.1 %)

0

0.286

 Diarrhea

2 (18.2 %)

1 (8.3 %)

0.484

 Vomiting

1 (9.1 %)

0

0.286

*significant p-value

Discussion

The superiority of concurrent chemoradiation therapy (CCRT) over surgical excision for LACC due to its more favorable local control and reduced adverse event rates was described in a recent report [17], and CCRT is now designated as a standard therapy for LACC. However, CCRT has several difficulties in terms of preserving the ovarian function, reducing late radiation-based adverse effects, and managing pelvic lesions which remain or recur after CCRT [18]. Thus, a therapeutically intensive alternative has been investigated, and NAC-RH has been designated as a reasonable alternative for LACC in terms of not only avoiding primary radiation therapy, but also the therapeutic intensity [19]. In this study, the response rate to NAC using CPT-11 and NDP was 76.3 %, consistent with a previous report [10] and not inferior to the combination of cisplatin and CPT-11 [20] or paclitaxel [21], but nearly one quarter of the cases were non-responders, and those with tumor shrinkage rates following NAC below 50 % showed shorter PFS. This was in agreement with a previous report that non-responders had poor prognostic outcomes [22]. Thus, the shrinkage rate was an independent prognostic factor, and it should be predicted prior to NAC to reduce the risk of the main treatment being delayed without NAC benefits.

Pharmacogenomic analysis using gene expression microarrays with chemo-sensitivity profiles has successfully identified several “signatures” which are characteristic gene profiles in cancers resistant to specific anti-cancer drugs [5], and been employed to discover novel drugs effective against chemo-resistant cancers [23]. In this study, GSEA showed that a mismatch repair pathway, a well-known signal of platinum-resistance, was enriched in non-responders. ssGSEA, which quantitatively scores the activity of each “signature” pathway in every sample based on gene expression microarray [7], revealed that the GMP score significantly increased in non-responders, and that there was a positive correlation between GMP scores and IC50 values of CPT-11 among 57 SCC cell lines. These results suggest that GMP scores may represent the susceptibility of LACC to CPT-11.

CPT-11 shows a strong anti-tumor activity not only via the inhibition of DNA synthesis but also the inactivation of cystine transporters, leading to the accumulation of reactive oxygen species (ROS) in cancer cells [24]. As the presence of ROS is an apoptosis-inducing stress, this mechanism associating with glutathione synthesis may support the idea that GMP activity represents CPT-11 susceptibility. There is, however, a limitation of this study in that GMP was identified through the analysis of post-NAC tumors, and to apply this pathway as a predictive biomarker of NAC susceptibility, further validation based on pre-NAC tumors is necessary. Nonetheless, unsupervised hierarchical cluster analysis of a web-published SCC gene expression microarray, GSE 6213, which contains paired samples of identical patients before/after chemotherapy, revealed the following: The gene expression pattern was not markedly affected by chemotherapy, since cluster dendrograms did not divide samples of each individual patient before/after chemotherapy (Additional file 3: Figure S3). As the GMP score showed a strong positive correlation with the total glutathione concentration in SCC cells and SCC cells with low GMP scores showed high sensitivity to CPT-11, the GMP score might be expected to act as an NAC-susceptibility biomarker representing intracellular glutathione synthesis.

In contrast, patients with heterozygotic polymorphism of UGT1A1 *1/*6 or *1/*28 (UGT1A1-poly patients) showed a shrinkage rate > 50 % without a high incidence of G3/4 toxicities. The finding that SKGIIIa cells with a high GMP score showed UGT1A1 polymorphisms and a high susceptibility to CPT-11 suggests that host UGT1A1 polymorphism may constitute a complementary marker of CPT-11 susceptibility in an organ-specific manner. In colorectal cancers, FOLFIRI containing CPT-11 was more effective in patients with UGT1A1*28/*28 polymorphism than UGT1A1-wild patients accompanied with a decrease of SN38 glucuronidation in the liver [25]. Patients with homozygous polymorphism had a much higher AUC ratio of SN-38 than wild-type patients, whereas patients with heterozygous polymorphism had a slightly higher AUC ratio than wild-type patients [25]. This may be the reason why NAC containing CPT-11 showed a higher efficacy without marked toxicity in patients with heterozygous polymorphisms. The UGT1A1 gene was picked up as one of the chemo-refractory signature genes in a genome-wide analysis [26], and UGT activation was observed in a colon cancer cell line which acquired resistance to CPT-11 [27]. We considered that the UGT1A1 genotypes of cancerous tissues matched those of the host, although there has been no report to date on the correlation of UGT1A1 polymorphisms between the tumor and host. Although further prospective studies are needed, NAC using CPT-11 in combination with UGT1A1 genotyping might be performed more effectively and safely than other regimens without such markers.

Conclusion

Based on comprehensive analysis, the present study suggests that the GMP score and heterozygotic UGT1A1 polymorphisms may be complementary predictive markers of CPT-11 efficacy. Other than CPT-11, a comprehensive genomic analysis of both host and cancerous tissue might facilitate the establishment of a novel tailored therapy for LACC patients that exhibits high-level efficacy and feasibility.

Abbreviations

NAC: 

Neoadjuvant chemotherapy

SCC: 

Squamous cell carcinoma

UGT1A1: 

UDP glucuronosyltransferase 1 family, polypeptide A1

LACC: 

Locally advanced cervical cancer

RH: 

Radical hysterectomy

GMP: 

Glutathione metabolic pathway

GSEA: 

Gene set enrichment analysis

PFS: 

Progression-free survival

LVSI: 

Lymphovascular invasion

IC50: 

Half maximal inhibitory concentration

Declarations

Acknowledgement

We are grateful to Yuko Hosoe, our laboratory technician, for her excellent technical assistance, and to the Medical Research Support Center of Kyoto University for DNA sequencing. This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI) from MEXT (The Ministry of Education, Culture, Sports, Science and Technology).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine

References

  1. Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, et al. Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group. Int J Gynecol Cancer. 2013;23(9):1655–60. quiz 1661–1652.View ArticlePubMedGoogle Scholar
  2. X. Xia, H. Xu, Z. Wang, R. Liu, T. Hu, S. Li: Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy. Am J Clin Oncol. 2014. epub ahead of print.Google Scholar
  3. Ferrandina G, Ercoli A, Fagotti A, Fanfani F, Gallotta V, Margariti AP, et al. Completion surgery after comcomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications. Ann Surg Oncol. 2014;21(5):1692–9.View ArticlePubMedGoogle Scholar
  4. Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol. 2013;39(2):115–24.View ArticlePubMedGoogle Scholar
  5. Balko JM, Black EP. Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature. Cancer Biol Ther. 2009;8(2):167–73.View ArticlePubMedGoogle Scholar
  6. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001;61(24):8654–8.PubMedGoogle Scholar
  7. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–12.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289–98.View ArticlePubMedGoogle Scholar
  9. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007;17(7):497–504.View ArticlePubMedGoogle Scholar
  10. Yamaguchi S, Nishimura R, Yaegashi N, Kiguchi K, Sugiyama T, Kita T, et al. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065). Oncol Rep. 2012;28(2):487–93.PubMedGoogle Scholar
  11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.View ArticlePubMedGoogle Scholar
  12. Fujii S, Takakura K, Matsumura N, Higuchi T, Yura S, Mandai M, et al. Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol. 2007;107(1):4–13.View ArticlePubMedGoogle Scholar
  13. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.View ArticlePubMedGoogle Scholar
  14. Broberg P. Statistical methods for ranking differentially expressed genes. Genome Biol. 2003;4(6):R41.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Choe SE, Boutros M, Michelson AM, Church GM, Halfon MS. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 2005;6(2):R16.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Fukui T, Mitsufuji H, Kubota M, Inaoka H, Hirose M, Iwabuchi K, et al. Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett. 2011;2(5):923–8.PubMedPubMed CentralGoogle Scholar
  17. Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 2012;6:CD005342.PubMedPubMed CentralGoogle Scholar
  18. Xiang EW, Shu-mo C, Ya-qin D, Ke W. Treatment of late recurrent vaginal malignancy after initial radiotherapy for carcinoma of the cervix: an analysis of 73 cases. Gynecol Oncol. 1998;69(2):125–9.View ArticleGoogle Scholar
  19. Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage Ib2 to IIb) cervical cancer: A randomized study. Gynecol Oncol. 2008;110(3):308–15.View ArticlePubMedGoogle Scholar
  20. Raspagliesi F, Ditto A, Selvaggi L, Frigerio L, Melpignano M, Scambia G, et al. A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer, International journal of gynecological cancer. Int J Gynecol Cancer. 2010;20(9):1569–75.PubMedGoogle Scholar
  21. Mousavia AS, Vahidi S, Karimi-Zarchi M, Modarress-Gilania M, Ghaemmaghamia F. Response to neoadjuvant chemotherapy with paclitaxel and cisplatin in locally advanced cervical cancer. Eur J Gynaecol Oncol. 2013;34(6):527–31.PubMedGoogle Scholar
  22. Zanaboni F, Grijuela B, Giudici S, Cormio G, Babilonti L, Ghezzi F, et al. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study. Eur J Cancer. 2013;49(5):1065–72.View ArticlePubMedGoogle Scholar
  23. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Chintala S, Toth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, et al. Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy. 2010;56(3):223–33.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D’Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer, Journal of clinical oncology. J Clin Oncol. 2006;24(19):3061–8.View ArticlePubMedGoogle Scholar
  26. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002;62(2):518–27.PubMedGoogle Scholar
  27. Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 2003;63(23):8443–50.PubMedGoogle Scholar

Copyright

© Horikawa et al. 2015

Advertisement